FERDINANDOS SKOULIDIS to ErbB Receptors
This is a "connection" page, showing publications FERDINANDOS SKOULIDIS has written about ErbB Receptors.
Connection Strength
0.596
-
Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer. Clin Cancer Res. 2017 Feb 01; 23(3):618-622.
Score: 0.299
-
Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. J Thorac Oncol. 2024 Oct; 19(10):1438-1448.
Score: 0.127
-
Co-occurring genomic alterations in?non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019 09; 19(9):495-509.
Score: 0.091
-
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 03; 19(3):500-506.
Score: 0.030
-
Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021 09; 597(7878):732-737.
Score: 0.026
-
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer. 2020 Jan 31; 20(1):83.
Score: 0.023